New hope for advanced blood cancers: experimental drug EP0042 enters human testing

NCT ID NCT04581512

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new experimental drug called EP0042 in adults with advanced acute myeloid leukemia (AML) or related blood cancers. The goal is to find a safe dose that might work against the cancer, either alone or with other treatments. About 70 participants will take part to check for side effects and see how the drug behaves in the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia chronic myelomonocytic leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Amsterdam UMC

    RECRUITING

    Amsterdam, 1081HV Amsterdam, Netherlands

  • Erasmus MC

    RECRUITING

    Rotterdam, 3000 CA Rotterdam, Netherlands

  • Royal Perth Hospital

    RECRUITING

    Perth, Western Australia, 6000, Australia

  • The Christie Hospital

    RECRUITING

    Manchester, M204BX, United Kingdom

  • The Royal Marsden

    RECRUITING

    London, UK, United Kingdom

  • University College London Hospital

    RECRUITING

    London, W1T 7HA, United Kingdom